“We evaluated the benefit/risk ratio of outpatient parenteral antimicrobial therapy (OPAT) in infective endocarditis (IE).” Lacroix et al (2014).
Reference:
Lacroix, A., Revest, M., Patrat-Delon, S., Lemaître, F., Donal, E., Lorléac’h, A., Arvieux, C., Michelet, C. and Tattevin, P. (2014) Outpatient parenteral antimicrobial therapy for infective endocarditis: A cost-effective strategy.
Médecine et Maladies Infectieuses. July 9th. [epub ahead of print].
[ctt tweet=”Outpatient parenteral antimicrobial therapy for infective endocarditis http://ctt.ec/r6u19+ @ivteam #ivteam” coverup=”r6u19″]
Abstract:
OBJECTIVES: We evaluated the benefit/risk ratio of outpatient parenteral antimicrobial therapy (OPAT) in infective endocarditis (IE).
METHOD: We performed an observational retrospective study of definite IE (Duke criteria) treated in an infectious diseases unit in 2012. We compared patients having completed the treatment in hospital (H), and those deemed sufficiently stable, and with adequate home environment, for OPAT. The costs were estimated through hospital bills, and, for OPAT, through the costs of drugs and their administration (material, staff), transportation, and outpatient visits.
RESULTS: Eighteen out of 39 consecutive patients presenting with IE received OPAT, with a mean hospital stay of 23.5days (vs 34.7days for H group, P=0.014). No severe adverse event related to OPAT was reported. The global saving was estimated at 267,307euros, or 14,850euros per patient.
CONCLUSIONS: OPAT in selected patients presenting with IE seems effective, safe, and reduces costs by approximately 15,000euros per patient.
Other intravenous and vascular access resources that may be of interest (External links – IVTEAM has no responsibility for content).
- Guide for intravenous chemotherapy and associated vascular access devices from Macmillan.
- CancerUK IV chemotherapy information.
